Evidence map›Paper›PMID 38766099›Full record

ArticlebioRxiv : the preprint server for biology2024

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.

Sumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, Saswati N Chand, Wei Yuan, Denisa Bogdan, Jon Welti, Adam Sharp, Natalie K Ryan, Matthew J Schiewer and 10 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Sumaira SardarCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 20817, USA.
Christopher M McNairSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, USA.
Lakshmi RavindranathCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 20817, USA.
Saswati N ChandSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, USA.
Wei YuanThe Institute of Cancer Research, London, United Kingdom.
Denisa BogdanThe Institute of Cancer Research, London, United Kingdom.
Jon WeltiThe Institute of Cancer Research, London, United Kingdom.
Adam SharpThe Institute of Cancer Research, London, United Kingdom.
Natalie K RyanSouth Australian Immunogenomics Cancer Institute, The University of Adelaide, Australia.
Matthew J SchiewerSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, USA.ORCID 0000-0002-2325-4228
Elise G DeArmentCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 20817, USA.
Thomas JanasCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 20817, USA.
Xiaofeng A SuCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 20817, USA.
Lisa M ButlerSouth Australian Immunogenomics Cancer Institute, The University of Adelaide, Australia.
Johann S de BonoThe Institute of Cancer Research, London, United Kingdom.
Kris FreseCellCentric Ltd., Cambridge, United Kingdom.
Nigel BrooksCellCentric Ltd., Cambridge, United Kingdom.
Neil PeggCellCentric Ltd., Cambridge, United Kingdom.
Karen E KnudsenThe American Cancer Society, Philadelphia, Pennsylvania, 19103, USA.
Ayesha A ShafiCenter for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 20817, USA.ORCID 0000-0003-0335-638X

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Claudio Guillermo Giraudo · 1995 to 2026
$94.8M
USP22 Function in Advanced Prostate CancerR01CA182569 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KNUDSEN, KAREN E, MCMAHON, STEVEN B. · 2015 to 2019
$2.4M
NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA182569Wellcome Trust
6 · The paper itself

Abstract

Castration resistant prostate cancer (CRPC) remains an incurable disease stage with ineffective treatments options. Here, the androgen receptor (AR) coactivators CBP/p300, which are histone acetyltransferases, were identified as critical mediators of DNA damage repair (DDR) to potentially enhance therapeutic targeting of CRPC. Key findings demonstrate that CBP/p300 expression increases with disease progression and selects for poor prognosis in metastatic disease. CBP/p300 bromodomain inhibition enhances response to standard of care therapeutics. Functional studies, CBP/p300 cistrome mapping, and transcriptome in CRPC revealed that CBP/p300 regulates DDR. Further mechanistic investigation showed that CBP/p300 attenuation via therapeutic targeting and genomic knockdown decreases homologous recombination (HR) factors

Indexed as

Androgen Receptor (AR)CBP/p300DNA repairnovel therapeuticsprostate cancer

Identifiers

PMID38766099
PMCPMC11100730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.